Last update 23 Apr 2025

Idecabtagene Vicleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-BCMA CART Cell Therapy - bluebird bio/Celgene, Anti-BCMA CART cells - bluebird bio/Celgene, ide-cel
+ [4]
Target
Action
inhibitors
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (03 Mar 2021),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (United States), Orphan Drug (United Kingdom), PRIME (European Union), Breakthrough Therapy (United States), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11556--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
United States
03 Mar 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 3
United States
30 Jan 2022
Relapse multiple myelomaPhase 3
United States
30 Jan 2022
BCMA Positive Multiple MyelomaPhase 1
United States
22 Dec 2015
BCMA Positive Multiple MyelomaPhase 1
United States
22 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
mcygnkcgku(ckkmnzmtuc) = ijhdovyabv usylrqmpcr (hbloezkmyu )
Similar
08 Dec 2024
mcygnkcgku(ckkmnzmtuc) = zqbepoodzh usylrqmpcr (hbloezkmyu )
Not Applicable
-
zxqtlfzfpf(ptzmbdyxbf) = hhsipvzppf sfnfqulrym (swnlzzfuqk )
-
24 May 2024
Not Applicable
351
(Extramedullary disease (EMD))
kdersttnkn(mnhynwbqqd) = ixewiidrko pkhmsylpds (tzuaecscld )
Negative
24 May 2024
kdersttnkn(mnhynwbqqd) = mauynxbpie pkhmsylpds (tzuaecscld )
Phase 2
35
dqlorketmu(avoetsinap) = fzpfmgzecq wxqiqqmrxu (ujfnqpyovd, 52 - 86)
Positive
14 May 2024
Not Applicable
817
IDECABTAGENE VICLEUCEL (IDE-CEL)
(Very Good Partial Response (VGPR) or better)
lxocnswrcf(desqelgkvv) = observed in SD and PD groups btgxofnjlt (duwtetomwf )
Positive
14 May 2024
IDECABTAGENE VICLEUCEL (IDE-CEL)
(Stable Disease (SD) or Progressive Disease (PD))
Not Applicable
Multiple Myeloma
sBCMA | circulating EVs
19
hakxilwduz(nfkwmlzcnh) = The presence of BCMA was observed and quantified in circulating EVs (these EVs were characterized by canonical EV-associated proteins). In most patients, the BCMA-content of plasma EVs showed a similar dynamic profile to that shown by sBCMA. wqlptvtrex (rgbnlvvjdy )
-
14 May 2024
Not Applicable
435
idecabtagene vicleucel (ide-cel)
idcfyuruac(aihzpubaxx) = lqoqkhabih otshtbmibq (fbhrrlycov, 5.3 - NR)
Positive
14 May 2024
BsAb (bispecific antibody)
lsiubgcsjo(eqjsqvtlnw) = dxwvfxtveh bwavwipucp (zjuhjizbxd )
Phase 3
-
nbhzrwabxi(naqsaajevr) = vynpqfrsdj dporykinhv (aoqcctcgow )
Positive
23 Apr 2024
Standard of care regimens
nbhzrwabxi(naqsaajevr) = impsqzhzxr dporykinhv (aoqcctcgow )
Not Applicable
110
BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapyide-celcilta-cel
cjgxnhhmek(uxxegpoyym) = dzukhjvhxm ukyagtqcju (tobjkkenvg )
Negative
01 Feb 2024
cjgxnhhmek(uxxegpoyym) = bgxodmewwx ukyagtqcju (tobjkkenvg )
Phase 3
Multiple Myeloma
soluble BCMA (sBCMA) concentration
226
zsjbcpiicd(eyoszubueh) = grquodlnjx xdpppwossr (tctxocteac, 8.9 - not reached)
Positive
01 Feb 2024
Standard Regimens (SRs)
zsjbcpiicd(eyoszubueh) = hmwfafscmy xdpppwossr (tctxocteac, 3.7 - 22.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free